Survival probabilities of EBV⁺ DLBCL-NOS vs EBV⁻ DLBCL-NOS patients treated with a curative-intent regimen. (A-B) PFS (A) and OS (B) for the 56 EBV⁺ DLBCL-NOS compared with the 425 EBV⁻ DLBCL-NOS cases. Both PFS and OS are not significantly between EBV⁺ DLBCL-NOS and EBV⁻ DLBCL-NOS. At 5 years, PFS of EBV⁺ DLBCL-NOS vs EBV⁻ DLBCL-NOS is 65.6% (95% CI, 59.2-72) and 49.6% (95% CI, 46.5-52.7), respectively (P = .180); and OS of EBV⁺ DLBCL-NOS vs EBV⁻ DLBCL-NOS is 68.3% (95% CI, 61.9-74.7) and 64.8% (95% CI, 61.6-68), respectively (P = .730).